Adrenocortical Cancer and IGF2: Is the Game Over or Our Experimental Models Limited?

Abstract excerpt

Adrenocortical cancer (ACC) is a rare (0.5–2 cases per million per year) but aggressive disease with low survival rates of 16 to 47%, depending on the clinical series. Although mitotane alone or in combination with chemotherapy can improve patients' survival, there is no efficient treatment of metastatic ACC, which is found in almost half of the patients at diagnosis. Identification of the molecular underpinnings...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adrenal and Paraganglionic Tumors
• Share to Cancer, Hypoxia, and Metabolism
• Share to Pituitary Gland Disorders and Treatments